

**REMARKS**

Claims 94-100 have been canceled without prejudice or disclaimer. Claims 101-105 have been added and therefore are pending in the present application. Claims 101-105 are supported by claims 94-100. As per the Examiner's request, the new presented claims do not use subscripts so that the claims can be read correctly when the USPTO scans the amendment.

The specification has been amended to delete the reference to the Danish priority application.

The Examiner informed the Undersigned that the amendments made in the Preliminary Amendment and Response to Notice to File Missing Parts and to Notice to Comply with Sequence Rules mailed October 12, 2001 were not entered because the paragraph and line numbers referenced therein were incorrect. This submission contains no new matter.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: March 10, 2006



Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097